Toxoplasmosis is a representative of the urgent need for new antiprotozoal targets. In addition to the fact that T. gondii is estimated to infect 2–3 billion people worldwide (Welti et al. 2007), its treatment is complicated due to two main factors: (a) the parasite undergoes a complex life cycle with two predominant forms in the human host, namely, tachyzoites (proliferative form) and bradyzoites (encysted form, chronic toxoplasmosis); (b) bradyzoite burden is widespread but usually asymptomatic, although it has been associated with psychiatric disorders (Webster et al. 2013). However, in immunocompromised individuals encysted T. gondii transform into proliferative tachyzoite forms causing symptomatic disease, toxoplasmic encephalitis. As such T. gondii is an opportunistic parasite. Notably, all the above-mentioned drugs act only against the tachyzoite stage with no notable effect against encysted bradyzoites (Antczak et al. 2016). Recent data from our laboratory (Alqaisi et al. 2017) and others (Sonda et al. 2005) have shown that the Aureobasidin A and analogous depsipeptides, known to target yeast SL biosynthesis (Wuts et al. 2015), exhibit activity against bradyzoite T. gondii. This class of compounds may offer a potential treatment for chronic toxoplasmosis and, perhaps, some psychiatric disorders; although the mechanism of action is not via inhibition of parasite SL biosynthesis and is yet to be elucidated (Alqaisi et al. 2017).